Inotek Pharmaceuticals Corporation to Present New Preclinical Data on Novel Mechanism of Action for Lead Glaucoma Candidate INO-8875
LEXINGTON, MA--(Marketwire - April 27, 2010) -
Highlighted Links |
Inotek Pharmaceuticals Corp. |
The poster presentations are as follows:
Sunday, May 2, 2010: 2:45 p.m. - 4:30 p.m. "Ocular Pharmacokinetics and Tissue Distribution of INO-8875, an Adenosine A1 Agonist, in Preclinical Species by Quantitative Whole Body Autoradiography (QWBA) and Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)" (Poster #A349) Tuesday, May 4, 2010: 1:45 p.m. - 3:30 p.m. "INO-8875, an Adenosine A1 Agonist, Lowers Intraocular Pressure Through the Conventional Outflow Pathway" (Poster #D780)
About Inotek
Inotek is a leader in the development of innovative drug candidates that address significant diseases of the eye, with a major focus on glaucoma. Inotek's lead product candidate INO-8875 is a potential first-in-class eye-drop treatment for glaucoma that significantly reduced intraocular pressure (IOP) in glaucoma subjects following single doses applied to the eye in a Phase 1/2 clinical trial. The Company believes INO-8875 will be a breakthrough treatment that can be used alone or combined with other IOP-lowering products because it increases the outflow of aqueous humor through the trabecular meshwork, the primary drainage system used by healthy elderly eyes to maintain normal IOP. The Company is also advancing a broad pipeline of PARP inhibitors and SOD mimetics that alleviate oxidative injury and inflammation, which it believes may address significant unmet medical needs in retinal diseases, such as the dry form of age-related macular degeneration (dry AMD). The Company is located in Lexington, MA. For further information on Inotek, please visit www.inotekcorp.com.
Company Information:
Adam L. Muzikant, Ph.D.
Senior Director, Business Development
Inotek Pharmaceuticals
(781) 676-2100
Media Relations:
Sarah Cavanaugh
MacDougall Biomedical Communications
Email Contact
(781) 235-3060